METABOLIC DYSFUNCTION AND ITS IMPACT ON DISEASE COURSE AND FIBROGENESIS IN CHRONIC HEPATITIS B: A REVIEW
Keywords:
Keywords: chronic hepatitis B; metabolic dysfunction-associated steatotic liver disease; fibrogenesis; gut microbiota; gut–liver axis.Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with chronic hepatitis B (CHB) in 14–70% of patients across cohorts, yet its impact on disease progression remains controversial [1]. We aimed to summarize current evidence on the pathogenetic mechanisms and clinical outcomes of concurrent CHB and metabolic dysfunction, with emphasis on the gut–liver axis in liver fibrogenesis.
References
1. Majeed AA, Butt AS. Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: rising pandemic with complex interaction. World J Hepatol. 2025;17(1):100968. doi:10.4254/wjh.v17.i1.100968
2. Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu J, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477(11):2481–2491. doi:10.1007/s11010-021-04143-z
3. Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1100–1109. doi:10.1111/apt.16595
4. Zhang N, Xu Z, Lin F, Fan H, Zhou D, Zheng S, et al. Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease. Front Cell Infect Microbiol. 2026;16:1806927. doi:10.3389/fcimb.2026.1806927
5. Shi K, Sun L, Feng Y, Wang X. Distinct gut microbiota and metabolomic profiles in HBV-related liver cirrhosis: insights into disease progression. Front Cell Infect Microbiol. 2025;15:1560564. doi:10.3389/fcimb.2025.1560564